{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:40:40Z","timestamp":1790487640669,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foch Hospital","award":["EOTP 11RAY163"],"award-info":[{"award-number":["EOTP 11RAY163"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.pupt.2018.01.003","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T02:56:59Z","timestamp":1515725819000},"page":"46-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus"],"prefix":"10.1016","volume":"49","author":[{"given":"Emmanuel","family":"Naline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Grassin Delyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Salvator","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Brollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Faisy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Victoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Abrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.pupt.2018.01.003_bib1","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1111\/bph.13348","article-title":"The Concise Guide to PHARMACOLOGY 2015\/16: G protein-coupled receptors","volume":"172","author":"Alexander","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2018.01.003_bib2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0163-7258(03)00004-4","article-title":"Muscarinic acetylcholine receptors and airway diseases","volume":"98","author":"Coulson","year":"2003","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.pupt.2018.01.003_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pupt.2012.12.006","article-title":"Long-acting muscarinic receptor antagonists for the treatment of respiratory disease","volume":"26","author":"Cazzola","year":"2013","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"10","key":"10.1016\/j.pupt.2018.01.003_bib4","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.rmed.2013.08.007","article-title":"Long-acting bronchodilators improve health related quality of life in patients with COPD","volume":"107","author":"Braido","year":"2013","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.01.003_bib5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.pupt.2015.02.007","article-title":"Assessing the clinical value of fast onset and sustained duration of action of long-acting bronchodilators for COPD","volume":"31","author":"Cazzola","year":"2015","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.pupt.2018.01.003_bib6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.rmed.2013.08.003","article-title":"The association between inhaled long-acting bronchodilators and less in-hospital care in newly-diagnosed COPD patients","volume":"108","author":"Kim","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.pupt.2018.01.003_bib7","series-title":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD","author":"GOLD","year":"2016"},{"issue":"139","key":"10.1016\/j.pupt.2018.01.003_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1183\/16000617.0052-2015","article-title":"Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?","volume":"25","author":"Busse","year":"2016","journal-title":"Eur. Respir. Rev."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/jpet.112.194456","article-title":"The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium","volume":"343","author":"Sykes","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5\u20136","key":"10.1016\/j.pupt.2018.01.003_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0024-3205(93)90312-Q","article-title":"Ba 679 BR, a novel long-acting anticholinergic bronchodilator","volume":"52","author":"Disse","year":"1993","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/jpet.109.151639","article-title":"Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile","volume":"331","author":"Gavalda","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pupt.2014.05.005","article-title":"The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide","volume":"28","author":"Gavalda","year":"2014","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/sj.bjp.0702573","article-title":"Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and Guinea-pig airways","volume":"127","author":"Haddad","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"6 Pt 1","key":"10.1016\/j.pupt.2018.01.003_bib14","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1164\/ajrccm.150.6.7952627","article-title":"Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in Guinea pig and human airways","volume":"150","author":"Takahashi","year":"1994","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2018.01.003_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjp.0706724","article-title":"Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in Guinea-pig and human airways","volume":"148","author":"Villetti","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2018.01.003_bib16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.110.170035","article-title":"Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist","volume":"335","author":"Villetti","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.pupt.2018.01.003_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.phrs.2015.07.033","article-title":"Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors","volume":"100","author":"Heusler","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.pupt.2018.01.003_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ejphar.2015.04.042","article-title":"Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi","volume":"761","author":"Rogliani","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1124\/jpet.112.202051","article-title":"Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases","volume":"345","author":"Salmon","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"11","key":"10.1016\/j.pupt.2018.01.003_bib20","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1111\/bph.12597","article-title":"Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors","volume":"171","author":"Grassin-Delyle","year":"2014","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2018.01.003_bib21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1183\/09031936.00032806","article-title":"Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi","volume":"29","author":"Naline","year":"2007","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.pupt.2018.01.003_bib22","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1152\/jappl.1988.64.6.2532","article-title":"Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and Guinea pig airways","volume":"64","author":"Minette","year":"1988","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.pupt.2018.01.003_bib23","series-title":"A Pharmacology Primer: Theory, Applications, and Methods","author":"Kenakin","year":"2010"},{"key":"10.1016\/j.pupt.2018.01.003_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2466-14-4","article-title":"A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study","volume":"14","author":"Chapman","year":"2014","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.pupt.2018.01.003_bib25","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.2147\/COPD.S106127","article-title":"Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)","volume":"11","author":"Marin","year":"2016","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.pupt.2018.01.003_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2466-14-118","article-title":"Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease","volume":"14","author":"Rennard","year":"2014","journal-title":"BMC Pulm. Med."},{"issue":"10","key":"10.1016\/j.pupt.2018.01.003_bib27","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.rmed.2010.04.006","article-title":"Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients","volume":"104","author":"Verkindre","year":"2010","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.pupt.2018.01.003_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/thorax.55.4.289","article-title":"A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group","volume":"55","author":"van Noord","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.pupt.2018.01.003_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/COPD.S102494","article-title":"A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD","volume":"11","author":"Feldman","year":"2016","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"4","key":"10.1016\/j.pupt.2018.01.003_bib30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/15412555.2013.814626","article-title":"Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study","volume":"10","author":"Beier","year":"2013","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.pupt.2018.01.003_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pupt.2009.08.001","article-title":"Aclidinium bromide provides long-acting bronchodilation in patients with COPD","volume":"23","author":"Chanez","year":"2010","journal-title":"Pulm. Pharmacol. Therapeut."},{"key":"10.1016\/j.pupt.2018.01.003_bib32","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2466-14-2","article-title":"Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study","volume":"14","author":"Church","year":"2014","journal-title":"BMC Pulm. Med."},{"issue":"7","key":"10.1016\/j.pupt.2018.01.003_bib33","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1183\/09031936.93.06071031","article-title":"Ba 679 Br, a new long-acting antimuscarinic bronchodilator: a pilot dose-escalation study in COPD","volume":"6","author":"Maesen","year":"1993","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.pupt.2018.01.003_bib34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.pupt.2012.03.008","article-title":"A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients","volume":"25","author":"Singh","year":"2012","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.pupt.2018.01.003_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1476-5381.2009.00296.x","article-title":"Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol","volume":"158","author":"Szczuka","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.pupt.2018.01.003_bib36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0165-6147(02)02081-3","article-title":"Models and methods for studying insurmountable antagonism","volume":"23","author":"Vauquelin","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib37","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/jpet.109.152470","article-title":"Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs","volume":"330","author":"Casarosa","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"8","key":"10.1016\/j.pupt.2018.01.003_bib38","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1111\/j.1476-5381.2011.01639.x","article-title":"Slow receptor dissociation is not a key factor in the duration of action of inhaled long-acting beta2-adrenoceptor agonists","volume":"165","author":"Sykes","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"7478","key":"10.1016\/j.pupt.2018.01.003_bib39","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse","year":"2013","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pupt.2018.01.003_bib40","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.113.090209","article-title":"Observed drug-receptor association rates are governed by membrane affinity: the importance of establishing \"micro-pharmacokinetic\/pharmacodynamic relationships\" at the beta2-adrenoceptor","volume":"85","author":"Sykes","year":"2014","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/0091270003261315","article-title":"Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment","volume":"44","author":"Turck","year":"2004","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.pupt.2018.01.003_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00609193","article-title":"Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration","volume":"36","author":"Ensing","year":"1989","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2018.01.003_bib43","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jps.21494","article-title":"Calculation of molecular lipophilicity: state-of-the-art and comparison of log P methods on more than 96,000 compounds","volume":"98","author":"Mannhold","year":"2009","journal-title":"J. Pharm. Sci."},{"issue":"D1","key":"10.1016\/j.pupt.2018.01.003_bib44","doi-asserted-by":"crossref","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","article-title":"PubChem substance and compound databases","volume":"44","author":"Kim","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.pupt.2018.01.003_bib45","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1021\/jm100068m","article-title":"The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist","volume":"53","author":"Baur","year":"2010","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.pupt.2018.01.003_bib46","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1021\/jm020886c","article-title":"QSAR and the rational design of long-acting dual D2-receptor\/beta 2-adrenoceptor agonists","volume":"46","author":"Austin","year":"2003","journal-title":"J. Med. Chem."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917301505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917301505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:17:11Z","timestamp":1693412231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553917301505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":46,"alternative-id":["S1094553917301505"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2018.01.003","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2018.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}